163 related articles for article (PubMed ID: 38657263)
1. How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults.
Tran TH; Tasian SK
Blood; 2024 Apr; ():. PubMed ID: 38657263
[TBL] [Abstract][Full Text] [Related]
2. Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
Tran TH; Tasian SK
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101331. PubMed ID: 34865703
[TBL] [Abstract][Full Text] [Related]
3. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.
Harvey RC; Tasian SK
Blood Adv; 2020 Jan; 4(1):218-228. PubMed ID: 31935290
[TBL] [Abstract][Full Text] [Related]
4. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
Pui CH; Roberts KG; Yang JJ; Mullighan CG
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
[TBL] [Abstract][Full Text] [Related]
5. Clinical screening for Ph-like ALL and the developing role of TKIs.
Tran TH; Tasian SK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):594-602. PubMed ID: 36485164
[TBL] [Abstract][Full Text] [Related]
6. Ph-like acute lymphoblastic leukemia.
Tran TH; Loh ML
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):561-566. PubMed ID: 27913529
[TBL] [Abstract][Full Text] [Related]
7. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.
Roberts KG; Gu Z; Payne-Turner D; McCastlain K; Harvey RC; Chen IM; Pei D; Iacobucci I; Valentine M; Pounds SB; Shi L; Li Y; Zhang J; Cheng C; Rambaldi A; Tosi M; Spinelli O; Radich JP; Minden MD; Rowe JM; Luger S; Litzow MR; Tallman MS; Wiernik PH; Bhatia R; Aldoss I; Kohlschmidt J; Mrózek K; Marcucci G; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Paietta E; Willman CL; Mullighan CG
J Clin Oncol; 2017 Feb; 35(4):394-401. PubMed ID: 27870571
[TBL] [Abstract][Full Text] [Related]
8. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
9. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
Khan M; Siddiqi R; Tran TH
Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
[TBL] [Abstract][Full Text] [Related]
10. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
11. Can Ph-like ALL be effectively targeted?
Maese L; Raetz EA
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101096. PubMed ID: 31779971
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts.
Ganguly S; Sasi A; Pushpam D; Bakhshi S
Indian J Pediatr; 2024 Jan; 91(1):37-46. PubMed ID: 37632689
[TBL] [Abstract][Full Text] [Related]
13. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
14. Integration of Next-Generation Sequencing in Diagnosing and Minimal Residual Disease Detection in Patients With Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
Sherali N; Hamadneh T; Aftab S; Alfonso M; Tsouklidis N
Cureus; 2020 Sep; 12(9):e10696. PubMed ID: 33133861
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibition enhances efficacy of dasatinib in
Gotesman M; Vo TT; Herzog LO; Tea T; Mallya S; Tasian SK; Konopleva M; Fruman DA
Oncotarget; 2018 Jan; 9(5):6562-6571. PubMed ID: 29464092
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus.
Couban S; Savoie L; Mourad YA; Leber B; Minden M; Turner R; Palada V; Shehata N; Christofides A; Lachance S
Curr Oncol; 2014 Apr; 21(2):e265-309. PubMed ID: 24764712
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
Jabbour E; Haddad FG; Short NJ; Kantarjian H
JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
